Ubs Group Ag Kiromic Biopharma, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.16 - $11.77 $3,239 - $238,307	20,247 Added 109.38%	38,757 $6,000
Q3 2022 Nov 10, 2022	BUY	$0.26 - $10.2 $3,472 - $136,221	13,355 Added 259.07%	18,510 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.26 - $0.87 $4,122 - $13,795	-15,857 Reduced 75.47%	5,155 $2,000
Q1 2022 May 16, 2022	BUY	$0.6 - $1.82 $10,862 - $32,949	18,104 Added 622.56%	21,012 $18,000
Q4 2021 Feb 14, 2022	BUY	$1.53 - $3.12 $4,449 - $9,072	2,908 New	2,908 $4,000
Q2 2021 Aug 13, 2021	SELL	$4.81 - $10.34 $8,412 - $18,084	-1,749 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$8.2 - $11.81 $155 - $224	19 Added 1.1%	1,749 $16,000
Q4 2020 Feb 11, 2021	BUY	$8.11 - $11.5 $14,030 - $19,895	1,730 New	1,730 $15,000

107K

Ticker KRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,843,200
Market Cap $16M
Description
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate tar...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.